Insmed (NASDAQ:INSM) shares advanced 4.7% on Monday as market participants digested two related catalysts: Morgan Stanley's upgrade on the stock and positive Phase 3 read-through from United Therapeutics' TETON-1 trial for Tyvaso.
Morgan Stanley moved its rating to Overweight from Equalweight and lifted its price target on Insmed to $212 from $166. The bank based its revision in part on results from an AlphaWise survey of 75 U.S. pulmonologists conducted in March 2026 examining the early adoption of Brinsupri for bronchiectasis. The survey found that 85% of respondents have already prescribed Brinsupri. Reported current patient share for Brinsupri was about 12%, with the surveyed physicians expecting that share to increase to roughly 21% by year-end.
The AlphaWise findings also indicated patterns consistent with repeat prescribing: respondents reported steady patient flow into pulmonology practices, low discontinuation rates, and refills progressing satisfactorily. Morgan Stanley cited that combination of initial uptake and refill behavior in raising its outlook.
Separately, United Therapeutics disclosed positive Phase 3 TETON-1 results for Tyvaso in idiopathic pulmonary fibrosis, showing a placebo-adjusted change in forced vital capacity of approximately 130 mL. That outcome compared favorably with the TETON-2 trial, which showed an approximate 96 mL placebo-adjusted change.
Several equity research teams framed the TETON-1 data as a read-through for Insmed's development plans. Jefferies kept a Buy rating and a $230 price target on Insmed, stating that the TETON-1 results validate the inhaled prostacyclin class in IPF and provide supportive context ahead of Insmed's planned Phase 3 trials of TPIP in IPF and in progressive pulmonary fibrosis expected in the second half of 2026.
Leerink Partners reiterated an Outperform rating with a $215 price target, noting that Insmed's TPIP franchise appears underappreciated even as Brinsupri sales are expected to ramp to more than $1 billion in 2026. Leerink also set an assumed peak sales figure of almost $5 billion for TPIP across multiple pulmonary indications.
Stifel also maintained a Buy rating and kept a $208 price target, commenting that the TETON-1 results remove a previously perceived overhang on Insmed shares, confirm treprostinil utilization in IPF, and should reduce perceived Phase 3 clinical development risk for TPIP.
Together, the survey-driven upgrade and the clinical read-through from United Therapeutics were cited by analysts as the principal drivers of the move in Insmed's share price on Monday.
- Market reaction: Insmed shares rose 4.7% on Monday following the analyst actions and clinical read-through.
- Analyst updates: Morgan Stanley upgraded to Overweight and raised its price target to $212; Jefferies, Leerink Partners, and Stifel maintained bullish ratings with price targets of $230, $215, and $208 respectively.
- Clinical and commercial signals: United Therapeutics reported TETON-1 showing a placebo-adjusted FVC improvement of approximately 130 mL versus roughly 96 mL in TETON-2; Morgan Stanley's survey showed early and increasing Brinsupri adoption among pulmonologists.